Biosyent Inc. (RX) Insider Alfred D’souza Sells 2,000 Shares of Stock

Share on StockTwits

Biosyent Inc. (CVE:RX) insider Alfred D’souza sold 2,000 shares of the company’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of C$10.03, for a total transaction of C$20,060.00.

Alfred D’souza also recently made the following trade(s):

  • On Wednesday, June 6th, Alfred D’souza sold 2,100 shares of Biosyent stock. The shares were sold at an average price of C$10.05, for a total transaction of C$21,105.00.

Biosyent traded down C$0.05, hitting C$9.80, during trading on Thursday, according to MarketBeat. 3,211 shares of the company’s stock traded hands, compared to its average volume of 7,777. Biosyent Inc. has a 12-month low of C$7.85 and a 12-month high of C$11.00.

Biosyent (CVE:RX) last posted its earnings results on Wednesday, March 21st. The company reported C$0.10 earnings per share for the quarter, hitting the Zacks’ consensus estimate of C$0.10. The company had revenue of C$5.90 million during the quarter. Biosyent had a net margin of 23.96% and a return on equity of 25.90%.

Several research firms have issued reports on RX. Bloom Burton restated an “accumulate” rating on shares of Biosyent in a research report on Thursday, March 22nd. Raymond James set a C$12.50 price target on shares of Biosyent and gave the company an “outperform” rating in a research report on Tuesday, May 1st.

About Biosyent

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Insider Buying and Selling by Quarter for Biosyent (CVE:RX)

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Axiom Price Reaches $0.0078 on Exchanges
Axiom Price Reaches $0.0078 on Exchanges
Starta Hits 24-Hour Trading Volume of $0.00
Starta Hits 24-Hour Trading Volume of $0.00
Zacks: Brokerages Expect MTS Systems Co.  Will Announce Earnings of $0.63 Per Share
Zacks: Brokerages Expect MTS Systems Co. Will Announce Earnings of $0.63 Per Share
Obalon Therapeutics  Getting Somewhat Positive Media Coverage, Study Shows
Obalon Therapeutics Getting Somewhat Positive Media Coverage, Study Shows
Novus Therapeutics  Receives News Impact Score of 0.16
Novus Therapeutics Receives News Impact Score of 0.16
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc  This Quarter
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc This Quarter


Leave a Reply

 
© 2006-2018 Zolmax.